Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

Latanoprostene bunod (LBN) 0.024%, a newly approved glaucoma eye drop, is metabolized into latanoprost acid and a nitric oxide (NO)-donating moiety, thus increasing the outflow of aqueous humor through the uveoscleral and trabecular routes, respectively. This study aimed to evaluate the intraocular...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Tzu-Chen, Chen, Yu-Yen, Hung, Man-Chen, Chou, Pesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331308/
https://www.ncbi.nlm.nih.gov/pubmed/35893417
http://dx.doi.org/10.3390/jcm11154325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331308/
https://www.ncbi.nlm.nih.gov/pubmed/35893417
http://dx.doi.org/10.3390/jcm11154325

Ejemplares similares